A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation

Lonnie Heijmans1,2, Martijn R Mons1,2, and Elbert A Joosten1,2

Abstract
Chronic neuropathic pain is a debilitating ordeal for patients worldwide and pharmacological treatment efficacy is still limited. As many pharmacological interventions for neuropathic pain often fail, insights into the underlying mechanism and role of identified receptors is of utmost importance. An important target for improving treatment of neuropathic pain is the descending serotonergic system as these projections modulate nociceptive signaling in the dorsal horn. Also with use of last resort treatments like spinal cord stimulation (SCS), the descending serotonergic projections are known to be involved in the pain relieving effect. This systematic review summarizes the involvement of the serotonergic system on nociceptive modulation in the healthy adult rodent and the chronic neuropathic rodent and summarizes all available literature on the serotonergic system in the SCS-treated neuropathic rodent. Medline, Embase and Pubmed databases were used in the search for articles. Descending serotonergic modulation of nociceptive signaling in spinal dorsal horn in normal adult rat is mainly inhibitory and mediated by 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3 and 5-HT4 receptors. Upon injury and in the neuropathic rat, this descending serotonergic modulation becomes facilitatory via activation of the 5-HT2a, 5-HT2b and 5-HT3 receptors. Analgesia due to neuromodulatory intervention like SCS restores the inhibitory function of the descending serotonergic system and involves 5-HT2, 5-HT3 and 5-HT4 receptors. The results of this systematic review provide insights and suggestions for further pharmacological and or neuromodulatory treatment of neuropathic pain based on targeting selected serotonergic receptors related to descending modulation of nociceptive signaling in spinal dorsal horn. With the novel developed SCS paradigms, the descending serotonergic system will be an important target for mechanism-based stimulation induced analgesia.

Keywords
Serotonin, 5-HT, dorsal horn, nociception, neuropathic pain, spinal cord stimulation

Date Received: 25 May 2021; Revised 1 August 2021; accepted: 16 August 2021

Introduction
Chronic neuropathic pain is an important worldwide problem that negatively impacts the quality of life of patients and imposes great socioeconomic costs.1 Neuropathic pain is a direct consequence of damage to the somatosensory nervous system, either through lesion or disease.2 In neuropathic pain, the processing of nociceptive information from not only the periphery to the spinal dorsal horn (DH) is completely derailed, but central processes including descending modulatory control from brainstem areas that innervate the DH are changed as well.1,3 Spinal cord stimulation (SCS) as a treatment for chronic neuropathic pain might be able to alter the derailed processing of nociceptive information and the descending modulation in the DH, thereby
providing analgesia. As the main neurotransmitter involved in descending modulation of spinal nociceptive neurotransmission is serotonin, the present review focuses on serotonergic descending projections. Virtually all serotonergic innervation of the spinal cord originates from supraspinal sources. Whereas the dorsal raphe nucleus (DRN) provides mainly ascending projections to other brain structures, the nucleus raphe magnus (NRM) provides serotonergic input to the spinal DH. Local 5-HT receptors mediate the net modulatory effect of 5-HT in the spinal DH (see Figure 1 and Table 1 for 5-HT receptor expression in spinal DH). Based on the receptors involved, the net effect of serotonergic descending modulation might be either inhibitory or facilitatory.

The main goal of this systematic review is to understand the role of descending serotonergic projection in chronic neuropathic pain (Descending serotonergic projections and spinal nociception in chronic neuropathic rodents section) and how SCS-induced pain relief in neuropathic pain acts via the modulation of these descending brainstem-spinal cord projections (Descending serotonergic projections and spinal nociception: Spinal cord stimulation in chronic neuropathic rodents section). The vast majority of literature is based on preclinical rodent studies. This review starts with summarizing the

![Figure 1](image-url). Descending serotonergic fibers and 5-HT receptors in the dorsal horn nociceptive network of the adult rat. Dorsal horn nociceptive network: Nociceptive afferent fibers (thinly myelinated Aδ-fiber, unmyelinated C-fiber) terminate in the superficial layers (lamina I-II) of the DH where they either synapse on interneurons (lamina I-III) or NK1 receptor expressing projection neurons (lamina I). Neurotransmitters utilized by inhibitory interneurons (ININs) are γ-aminobutyric acid (GABA), glycine, or both. Excitatory interneurons (EXIN) utilize glutamate. The interneurons synapse on projection neurons either in lamina I (nociceptive specific) or in lamina III-V (wide dynamic range (WDR) neurons). WDR neurons have dendrites extending to the superficial lamina and thus synapses form nociceptive fibers, non-nociceptive fibers and interneurons. Non-noxious stimuli are transmitted by touch-responsive, myelinated Aβ fibers that terminate within lamina II-V and synapse onto the WDR and interneurons. Descending serotonergic neurons terminate most abundantly in the superficial laminae (I/III) but they also innervate deeper laminae (IV-VI). Panel (b) depicts the enlarged inset of (a) and contains numbered pathways of 5-HT mediated nociceptive modulation: 1) Autoreceptor pathway; direct modulation of serotonin release through 5-HT1b autoreceptors on descending serotonergic terminals. 2) Projection neuron pathway; direct modulation through postsynaptic 5-HT3 and 5-HT5a expression on spinal projection neurons. 3) GABA ININ pathway; indirect modulation of projection neurons through 5-HT1a, 5-HT2a, 5-HT3 and 5-HT7 receptors on GABAergic ININs. 4) EXIN pathway; indirect modulation of projection neuron through 5-HT3 and 5-HT5a expression on EXINs. 5) Nociceptive afferent pathway; direct modulation of neurotransmitter release through expression of 5-HT1a, 5-HT1b, 5-HT2a, 5-HT3 and 5-HT7 on nociceptive afferent terminals. 6) Non-nociceptive afferent pathway; modulation via activation of GABAergic ININs by non-nociceptive afferents (Aβ fibers) according to the principle of the Gate-Control Theory.

![Diagram](image-url)
present literature on descending serotonergic brainstem-
spinal cord projections in the normal (Descending sero-
tonergic projections and spinal nociception in adult
rodent section) and in the neuropathic rat (Descending
serotonergic projections and spinal nociception in chron-
ic neuropathic rodents section). The Descending seroto-
nergic projections and spinal nociception: Spinal cord
stimulation in chronic neuropathic rodents section sum-
arizes literature on SCS in modulation of descending
serotonergic brainstem-spinal cord projections and pain
relief. In the Summary and discussion section, results are
summarized and discussed, limitations and future per-
spectives are presented.

Methods
A systematic literature search was conducted using
Pubmed, Medline and Embase search engines. Search
terms and strategy for each database are included in
Appendix 1. Literature searches were performed until
May 15, 2020 by one reviewer (LH). No date limits
were applied to the search but selected articles were
restricted to the English language. Only articles on the
serotonergic system relating to either healthy nocicep-
tion, peripheral chronic pain models and/or neurostimu-
lation were included. Only preclinical studies on rodents
were included. Articles included in the review must be
original studies, reviews resulting from the search were
screened for the inclusion of additional articles. A full
overview of inclusion and exclusion criteria is included in
Appendix 2.

Search results were uploaded in Endnote to screen for
eligibility and to remove duplicate results. An initial
screening based on title and abstract was performed to
exclude irrelevant articles or articles that did not meet
inclusion criteria. Remaining articles were read in full
and excluded if they did not meet inclusion criteria. All
articles included in the results section of the review
\((n=85)\) were either included from the search or referred
to by included articles. A flow diagram of study selection
is presented in Appendix 3. One reviewer (LH) collected
the following study characteristics from the included
articles; first author, species, sex, pain model, treatment,
assessment measures (Appendix 4).

All articles included in the result section of the review
\((n=85)\) were subjected to a Risk of Bias (RoB) analysis
to assess the individual quality of the articles. The
SYRCLE RoB tool was used for this evaluation. The
items in the RoB tool relate to performance bias, selec-
tion bias, attrition bias, detection bias, reporting bias
and other biases.27 RoB analysis was performed inde-
pendently by two reviewers (LH, MRM) and their
assessment was compared after completion of the anal-
ysis. Differences in assessment were discussed and a con-
sensus was reached for each article. Appendix 5 provides
RoB analysis for each individual article.

Results

**Descending serotonergic projections and spinal
nociception in adult rodent**

The release of serotonin in the spinal dorsal horn acti-
vates the various serotonin receptors and thereby modu-
lates nociceptive input to the spinal dorsal horn and the
subsequent signal transmission to the brain (i.e. opening
or closing the spinal gate). Serotonin has a bidirectional
effect on spinal nociceptive processing and, through its

| Table 1. 5-HT receptor expression on different cell types within the dorsal horn of the spinal cord. |
|--------------------------------------------------|---|---|---|---|
| Nociceptive afferent | Projection neuron | Inhibitory interneuron (GABAergic) | Excitatory interneuron | Descending serotonergic terminal |
|----------------------|------------------|---------------------------------|----------------------|---------------------------------|
| **Inhibitory receptors** |
| 5-HT1a               | ✓                | ✓                              | ✓                    | -                               |
| 5-HT1b               | ✓                | ?                              | ?                    | ✓                               |
| 5-HT1d               | ✓                | ?                              | ?                    | ?                               |
| 5-HT5a               | ✓                | ✓                              | ✓                    | -                               |
| **Excitatory receptors** |
| 5-HT2a               | ✓                | ?                              | ✓                    | ✓                               |
| 5-HT2b               | ✓                | ?                              | ?                    | ✓                               |
| 5-HT2c               | ✓                | ?                              | ?                    | ?                               |
| 5-HT3                | ✓                | ✓                              | ✓                    | -                               |
| 5-HT4                | ?                | ✓                              | ✓                    | ✓                               |
| 5-HT6                | ?                | ✓                              | ✓                    | ✓                               |
| 5-HT7                | ✓                | ✓                              | ✓                    | -                               |

✓: receptor present on cell type; –: receptor not present on cell type; ?: unknown.
receptors, either facilitates or inhibits the incoming nociceptive signal (opening or closing the spinal gate, respectively).26

Excitatory receptors in the spinal DH are 5-HT2 (Gq coupled), 5-HT3 (ligand-gated ion channel), 5-HT4, 5-HT6 and 5-HT7 (Gi coupled). Inhibitory receptors in the spinal DH are 5-HT1 and 5-HT5 (Gi coupled).4,28

Essentially the net effect of the activation of 5-HT receptors depends on which receptor subtype is activated, either inhibitory (see the next section) or facilitatory (see the Descending serotonergic projections and facilitation of spinal nociception section), to what degree and on which cell type these receptors are located (see Figure 1(b)). If inhibitory 5-HT receptors are expressed on inhibitory interneurons, the net effect is facilitatory, and vice versa.

**Descending serotonergic projections and inhibition of spinal nociception.** Involvement of spinal serotonin in inhibition of nociception has been demonstrated both behaviorally29,30 and in electrophysiological studies.13,31 Fasmer et al. suggested that serotonin in the spinal cord tonically inhibits reflex based nociception, as serotonin depletion has pronociceptive influences on the tail flick reflex.32 Not only spinal, but also systemic and supraspinal administration of serotonin or its precursor 5-hydroxytryptophan (5-HTP) has antinociceptive effects on the tail flick reflex.33-37 However, caution should be taken while interpreting tail flick test results as serotonin or its agonists can produce motor effects that possibly influence tail flicks.36,37

The inhibitory modulation of 5-HT on nociceptive transmission in the DH is mediated by 5-HT1a, 5-HT1b, 5-HT2a, 5-HT2c, 5-HT3 and 5-HT4 receptors. Evidence for the antinociceptive effect of 5-HT1a has been provided by both behavioral38-40 and electrophysiological studies.39,41-43 The inhibitory modulation of nociception via the 5-HT1a receptor is likely mediated via a reduced glutamate release from primary afferent terminals (nociceptive afferent pathway, Figure 1(b)). There is, however, one electrophysiological study that shows that spinal 5-HT1a activation does not influence C fiber-evoked spinal field potentials.44

The inhibitory effect of spinal 5-HT1b receptor evoked responses of DH neurons was demonstrated through spinal administration of 5-HT1b agonists13,45,46 and antagonists.13 However, there is some discrepancy in literature about the involvement of 5-HT1b receptors in nociceptive processing as it has been shown that spinal 5-HT1b agonists did not affect reflex-based nociceptive behavior39,46 or evoked wide dynamic range (WDR) neuronal responses.39 5-HT1b autoreceptors are expressed on descending serotonergic terminals,10 where they inhibit 5-HT release in the DH47 (autoreceptor pathway, Figure 1(b)). The described discrepancy on 5-HT1b functionality in descending inhibition of nociception in the spinal cord may be due to the dual effect on both the autoreceptor pathway and the nociceptive afferent pathway, yet this remains to be investigated.

Spinal 5-HT2a receptors are not involved in the inhibition of neuronal responses in DH laminae I and II44 nor in nociceptive behavior.48 However, involvement of spinal 5-HT2a receptors in nociceptive inhibition cannot be completely ignored as activation of spinal 5-HT2a receptors inhibits C fiber-evoked WDR responses.13 This inhibitory effect is likely exerted indirectly via the excitatory interneuron (EXIN) pathway (see Figure 1(b)).

Spinal 5-HT3 agonists produce antinociceptive behaviors49-51 whereas spinal 5-HT3 antagonists or 5-HT3 receptor knock-down increase sensitivity to nociceptive stimuli and reduce inhibitory effects of exogenous 5-HT.49-52 Electrophysiological studies report inhibitory effects of 5-HT3 receptors.13,42,53 Alhaider et al. demonstrated that this inhibitory modulation was mediated by γ-aminobutyric acid (GABA).49 Thus, 5-HT3 receptor activation involves the GABAergic inhibitory interneuron (ININ) pathway (see Figure 1(b)). Despite the fact that the expression of 5-HT2c and 5-HT4 in the DH has not been specified, it has been shown that activation of these receptors inhibits C fiber-evoked responses of WDR neurons.13,44,54

Little is known about the functionality of the inhibitory 5-HT5a receptor. Although, one would expect, based on its expression on exclusively postsynaptic neurons in the DH, the 5-HT5a receptor to be involved in descending inhibition via both the projection neuron pathway and the EXIN pathway11 (see Figure 1(b)).

**Conclusion:** In the healthy adult rodent, serotonin is inhibiting spinal nociceptive neurotransmission. This anti-nociceptive effect is mediated via 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3 and 5-HT4 receptors. Although 5-HT3 is originally excitatory, the presence of this receptor on inhibitory GABAergic interneurons makes its activation resulting also in an inhibitory net-effect on spinal nociceptive neurotransmission.

**Descending serotonergic projections and facilitation of spinal nociception.** Despite overwhelming evidence of antinociceptive effects of centrally administered serotonin in healthy adult rodents (see the previous section), serotonin also may facilitate nociceptive transmission in the spinal dorsal horn. Cai et al. showed that optogenetic activation of serotonergic neurons in the RVM produced persistent sensitization to mechanical and thermal stimuli and suggested that serotonergic neurons in the RVM have a predominant facilitatory role on spinal nociception.55

Indeed, pronociceptive behaviors in the healthy rodent have been induced by both spinal and systemic...
5-HT1a receptor activation. This facilitatory action of the inhibitory 5-HT1a receptor likely involves the GABA ININ pathway (see Figure 1(b)), as 5-HT1a receptors are expressed on GABAergic interneurons. Bonnefont et al. provided evidence for this by showing that the facilitatory effect of spinal 5-HT1a receptors could be inhibited by the GABA_A receptor antagonist bicuculline. Spinal 5-HT1b receptor activation was shown to increase electrically evoked post-discharge and it was therefore suggested that this probably enhanced the excitability of the GABAergic neurons.

Spinal non-specific 5-HT2a/c agonists and antagonists revealed facilitatory effects on evoked WDR responses. Whether this facilitatory effect is due to 5-HT2a or 5-HT2c mediated modulation remains to be investigated.

Besides a vast amount of evidence showing inhibitory effects of 5-HT3 receptor activation (via the GABAergic interneurons; see the previous section), activation of this receptor has also been shown to result in pronociceptive modes of action. This facilitatory effect of 5-HT3 receptors can be explained by its expression on primary afferent terminals (nociceptive afferent pathway, see Figure 1(b)), on excitatory interneurons (EXIN pathway, see Figure 1(b)) and/or on projection neurons (projection neuron pathway, Figure 1(b)). Guo et al. demonstrated that the facilitatory effect of spinal 5-HT3 activation was dose-dependent, as the highest dose of 5-HT3 agonist they used produced antinociceptive effects.

Spinal 5-HT2b and 5-HT7 receptors do not seem to play a key role in the modulation of nociception in the sham-injured rodent and therefore might not be involved in serotonergic modulation of nociceptive processing in the DH.

**Conclusion:** Facilitatory effects of descending serotonergic modulation on spinal nociception do exist in the healthy adult rodent and are mediated via activation of 5-HT1a, 5-HT2a/c and 5-HT3 receptors.

In conclusion. In the healthy adult rodent there is an overall inhibitory and anti-nociceptive effect of serotonin on spinal nociceptive processing. The ability of descending serotonergic projections to modulate inhibition as well as facilitation of the spinal nociceptive network depends on the receptors involved in relation to their cellular localization. The inhibitory modulation of 5-HT on nociceptive transmission in the DH of the healthy adult rodent is mediated via activation of 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3 and 5-HT4 receptors whereas facilitatory modulation is mediated by 5-HT1a receptors, 5-HT2a/c receptors and 5-HT3 receptors. Spinal 5-HT2b and 5-HT7 receptors are very likely not involved in descending serotonergic modulation of the spinal nociception (see Figure 2(a)).

**Descending serotonergic projections and spinal nociception in chronic neuropathic rodents**

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Injury to peripheral nerves induces a variety of plastic changes in the DH, such as glutamate/NMDA-mediated central sensitization, disinhibition and altered neuron-glia interactions, all contributing to the development and maintenance of chronic neuropathic pain. The descending serotonergic...
system is also subject to changes during the development of neuropathic pain.

**Descending serotonergic projections and inhibition of spinal nociception in neuropathic pain.** The descending serotonergic system is subject to changes after nerve injury which disturbs the balance between inhibitory and facilitatory modulation of nociceptive transmission in the spinal DH. Changes in 5-HT mediated descending inhibition may contribute to the facilitatory effect of serotonin on nociceptive transmission in peripheral neuropathic pain models. In part, this might involve a decrease of 5-HT in the spinal DH as observed in various peripheral nerve injury models. Indeed, spinally 5-HT depleted rats are more sensitive upon CCI than non-depleted controls. On the other hand, levels of spinal 5-HT have also been shown to be increased or unchanged after injury, depending on the neuropathic pain model used.

Alongside the decrease in spinal 5-HT, 5-HT receptors are also subject to changes upon injury. The contribution of spinal 5-HT1 receptors (1a and 1b) to neuropathic pain remain still somewhat unclear. Although 5-HT1a receptors have been documented to be inhibitory to nociceptive neurotransmission in neuropathic pain models, other studies suggest spinal 5-HT1a not to be involved in inhibition or to lose this inhibitory action. A similar incomplete picture exists for the spinal 5-HT1b receptor where on the one hand Liu et al. demonstrated a loss of inhibitory function of spinal 5-HT1b receptors using both agonist and antagonist application, but on the other hand an unchanged inhibitory role was reported.

The spinal 5-HT2c receptors are involved in inhibitory modulation of nociceptive neurotransmission as activation of the spinal 5-HT2c receptor resulted in antiallodynic behaviors in a peripheral SNL injury model. On the other hand, pharmacological inhibition of spinal 5-HT2c receptors resulted in a loss of effect on 5-HT-evoked WDR neuron activity. It is therefore possible that SNL injury reduces the inhibitory effects of 5-HT2c on WDR neurons but does not diminish inhibitory 5-HT2c function completely. In the setting of peripheral nerve injury, spinal non-specific 5-HT2a/2c activation seems to switch from a facilitatory effect on nociceptive neurotransmission to promoting behavioral analgesia. Additionally, these receptors are involved in the antinociceptive effect of SSRIs.

The spinal 5-HT3 receptor loses its inhibitory effect on evoked WDR responses after SNL injury. At the same time, increased expression of 5-HT3 receptors on primary afferent terminals after CCI of the infraorbital nerve have been suggested by Kim et al. Increased activation of the nociceptive afferent pathway (see Figure 1(b)) due to increased 5-HT3 expression could explain the reduced inhibitory effect on evoked WDR responses. Additionally, Peters et al. did not report an effect of various doses of i.t. the 5-HT3 antagonist ondansetron on mechanical and thermal hypersensitivity 14 days after SNL injury. At the same time, intrathecal 5-HT3 agonist m-CPBG application resulted in antiallodynic effects, which is mediated by GABA. Thus, the inhibitory modulation observed in healthy rats does not seem to be completely abolished.

The 5-HT4 receptor loses its inhibitory function on nociceptive neurotransmission in chronic neuropathic pain models. 5-HT5a receptors are involved in mediating antinociceptive effects of exogenously administered 5-HT in the SNL model of chronic neuropathic pain whereas 5-HT5a receptor protein levels are not altered.

Although the 5-HT7 receptor does not seem to play a major role in the modulation of nociceptive transmission in the healthy rodent, both systemic and spinal activation of the 5-HT7 receptor produced antinociception in various neuropathic pain models. This related to activation of the GABAergic system (see Figure 1(b); GABAergic ININ pathway). 5-HT7 receptor expression was shown to be increased in lamina I-II and III-V of the ipsilateral DH in the PSNL mice, whereas 5-HT7 expression is not increased on GABAergic ININs. Thus, injury might change the proportions of 5-HT7 receptors expressed on different cell types, causing changes in receptor function upon injury.

**Conclusion:** In neuropathic pain, the facilitatory modulation of nonspecific 5-HT2a/c receptors switches to an inhibitory modulation. Serotonergic inhibitory modulation is further mediated by 5-HT2c and 5-HT3 receptors in the chronic neuropathic animal. 5-HT5a receptors are also involved in inhibiting nociceptive signaling in the chronic neuropathic rat whereas its function in the healthy rodent is relatively unknown. The 5-HT7 receptor seems to gain an inhibitory function in modulation of nociceptive signaling upon injury. 5-HT1a and 5-HT1b receptors may also be involved in mediating 5-HTergic descending inhibition, however inconsistencies in the literature do not allow for a definitive conclusion.

**Descending serotonergic projections and facilitation of spinal nociception in neuropathic pain.** Whereas spinal serotonin in healthy nociception has an overall antinociceptive effect (see the Descending serotonergic projections and inhibition of spinal nociception section), peripheral nerve injury seems to result in a more facilitatory effect of spinal serotonin. This has been shown by several studies on different types of peripheral injury models where spinal or supraspinal serotonin depletion reversed the hypersensitivity induced by the injury induced by the pain model and altered evoked responses of WDR.
neurons to punctuate mechanical and heat stimuli. These analgesic effects of serotonin depletion suggest that serotonin facilitates nociceptive transmission in peripheral neuropathic pain. A study by Vogel et al. reinforces this statement by showing that mice deficient of the serotonin transporter (5-HTT), which is normally expressed on descending serotonergic terminals, do not develop heat hyperalgesia upon CCI of the sciatic nerve. These mice showed a reduced serotonin content in their spinal cord compared to their wild type littermates, which may explain the lack of heat hyperalgesia in these mice. Therefore, the authors conclude that serotonin is involved in the sensitization of nociceptive fibers to heat stimuli.

Spinal 5-HT2a and 5-HT2b receptors seem less important for nociceptive modulation in healthy rodents, but on the contrary their activation is involved in facilitation of C fiber-evoked responses after SNL. The facilitatory role of spinal 5-HT2a receptors in chronic neuropathic pain has also been demonstrated in other studies. In addition, systemic 5-HT2a activation has been shown to result in pronociceptive effects. The facilitatory effects of 5-HT2a and 5-HT2b receptors may be explained by increased expression of these receptors in the spinal DH upon injury. These mice showed a reduced serotonin content in their spinal cord compared to their wild type littermates, which may explain the lack of heat hyperalgesia in these mice. Therefore, the authors conclude that serotonin is involved in the sensitization of nociceptive fibers to heat stimuli.

As previously mentioned, there is evidence for 5-HT7 receptors upon SNL injury has also been reported. These mice showed a reduced serotonin content in their spinal cord compared to their wild type littermates, which may explain the lack of heat hyperalgesia in these mice. Therefore, the authors conclude that serotonin is involved in the sensitization of nociceptive fibers to heat stimuli.

Spinal 5-HT2a and 5-HT2b receptors seem less important for nociceptive modulation in healthy rodents, but on the contrary their activation is involved in facilitation of C fiber-evoked responses after SNL. The facilitatory role of spinal 5-HT2a receptors in chronic neuropathic pain has also been demonstrated in other studies. In addition, systemic 5-HT2a activation has been shown to result in pronociceptive effects. The facilitatory effects of 5-HT2a and 5-HT2b receptors may be explained by increased expression of these receptors in the spinal DH upon injury. These mice showed a reduced serotonin content in their spinal cord compared to their wild type littermates, which may explain the lack of heat hyperalgesia in these mice. Therefore, the authors conclude that serotonin is involved in the sensitization of nociceptive fibers to heat stimuli.

As described in the previous section, 5-HT7 receptors seem to be involved in nociceptive inhibition upon injury. However, one study suggests a facilitatory and pronociceptive effect of 5-HT7 receptors in chronic neuropathic pain. In SNL animals antinociceptive effects of spinal and systemic 5-HT7 inhibition and a reduced 5-HT7 protein content in DH tissue ipsilateral to injury was shown. These functional differences may be explained by differences in receptor expression and/or protein content as increased 5-HT7 expression was involved in inhibitory antinociceptive effects and the facilitatory pronociceptive effect was observed with reduced 5-HT7 protein content.

Conclusion: The balance between facilitation and inhibition of 5-HT tips towards facilitation of nociceptive transmission after injury. Especially 5-HT2a, 5-HT2b and 5-HT3 receptors are involved in mediating the facilitatory effect of 5-HT in the spinal DH. The 5-HT2b receptor seems to gain this function as evidence for its involvement in the modulation of nociceptive transmission in the healthy rodent is lacking.

In conclusion. Descending serotonergic projections are mainly facilitating spinal nociception in chronic neuropathic rodents. This pro-nociceptive effect is in contrast to the anti-nociceptive effect of the descending serotonergic project in normal healthy adult rat (see the Descending serotonergic projections and spinal nociception in adult rodent section). This shift from inhibitory to facilitatory mode of action is related to both injury-induced changes in 5-HT content as well as in increased expression of excitatory serotonergic receptors 5-HT2a, 5-HT2b and 5-HT3 receptors and the loss of inhibitory function of 5-HT1b and 5-HT4 receptors (see Figure 2(b)). It should be noted that the use of different preclinical models for chronic neuropathic pain resulted in different outcomes and may explain some of the inconsistencies reported.

Descending serotonergic projections and spinal nociception: Spinal cord stimulation in chronic neuropathic rodents

In the context of chronic neuropathic pain, spinal cord stimulation of the dorsal columns (DC-SCS) is an important treatment option. Although still used as a last resort option, it has been shown to result in significant pain relief of patients which did not respond to pharmacological treatment. The mechanism of conventional (con)-DC-SCS in neuropathic pain is based on the Gate Control Theory and an antidromic effect from the Aβ fibers in the dorsal columns to the nociceptive network in the spinal dorsal horn. The reviewed studies in this section all utilized the con-DC-SCS paradigm. This type of stimulation, also called tonic SCS, delivers equally spaced pulses at a frequency typically ranging between 40–80 Hz. In an elegant series of experiments it was shown that the pain relieving effect of con-DC-SCS is related to a (major) segmental effect but at the same time a supraspinal loop is stimulated. How this supraspinal loop is stimulated is not yet exactly known but in this loop the read-out can be monitored by the activity of descending serotonergic fibers and its modulation of spinal nociception. The involvement of 5-HT in a con-DC-SCS-activated supraspinal loop is further demonstrated by Tazawa et al. In addition, they suggest that 5-HT is less involved in the segmental mechanisms of SCS-induced antinociception but is more related to the onset of a supraspinal loop and mechanism (for review on mechanism of con-DC-SCS see
Joosten and Franken, 2020). Con-DC-SCS was shown to induce a decrease of tryptophan hydroxylase (TPH, the 5-HT synthetic enzyme) protein levels in the ipsilateral dorsal quadrant of the lumbar SC but at the same time induced an increased number of TPH positive cells in the dorsal raphe nucleus. Additionally, con-DC-SCS has been shown to result in increased 5-HT release in the DH in rats with PSNL-induced neuropathic pain. This increased 5-HT in the superficial DH was observed only in rats responding to SCS treatment (i.e. responders). Therefore, it is concluded that the increased spinal 5-HT is involved in the anti-nociceptive mechanisms of con-DC-SCS.

Besides the con-DC-SCS paradigm, the field of spinal cord stimulation has developed additional stimulation paradigms and has ventured to new stimulation locations (also reviewed in Joosten and Franken, 2020). The use of new paradigms like burst-SCS have been suggested to induce a stronger activation of the supraspinal loop as compared to the use of con-DC-SCS (see the Cortical control of descending 5-HT modulation section) and thus these paradigms may preferentially involve the descending serotonergic system.

Descending serotonergic projections and inhibition of spinal nociception with conventional DC-SCS. Studies aimed to characterize which 5-HT receptors are involved in the con-DC-SCS mediated antinociception have revealed that subclinical doses of intrathecal 5-HT2a receptor antagonist and 5-HT4 receptor antagonist counteract the con-DC-SCS-induced analgesic effects. Systemic administration of the non-selective 5-HT2a/2c receptor antagonist ketanserin significantly reduces the antinociceptive effect of con-DC-SCS. This suggests that, in addition to spinal 5-HT2 receptors, either peripheral or supraspinal 5-HT2 receptors are involved in the antinociceptive effect of con-DC-SCS as well.

A loss of inhibitory function of 5-HT4 receptors is involved in development of chronic neuropathic pain (see the Descending serotonergic projections and spinal nociception in chronic neuropathic rodents section) and con-DC-SCS reverses this effect, which results in antinociceptive outcome. As the 5-HT4 receptor is facilitatory, it is therefore likely that its involvement in the analgesic effect of con-DC-SCS is mediated via inhibitory interneurons, the same goes for the 5-HT2a and 5-HT3 receptor. Evidence for the involvement of the GABAergic ININ pathway (see Figure 1(b)) in 5-HT3 mediation of con-DC-SCS induced antinociception is provided by Song et al. They showed that i.t. application of a sub-effective dose of m-CPBG, a 5-HT3 receptor agonist, enhanced con-DC-SCS pain relieving effect, and then this was eliminated by i.t. application of the GABA A antagonist bicuculline.

Spinal 5-HT1 receptors may also be involved in mediating the analgesic effects of con-DC-SCS because i.t. administration of methysergide reversed the analgesic effects of SCS. It should be kept in mind that methysergide is a relatively unspecific antagonist that binds both 5-HT1 and 5-HT2 receptor subtypes and thus the exact involvement of spinal 5-HT1 receptor subtype remains unclear.

Conclusion: Con-DC-SCS results in antinociception and reverses the pronociceptive effect of the descending serotonergic projections as seen in chronic neuropathic rodents. Con-DC-SCS increases 5-HT release in the DH in chronic neuropathic rodents. This change from a pro- to an antinociceptive effect is mediated via 5-HT2 and 5-HT3 receptors. At the same time con-DC-SCS restores inhibitory function of the 5-HT4 receptor that was lost upon injury.

Descending serotonergic projections and facilitation of spinal nociception with conventional DC-SCS. Our search did not result in any articles which demonstrated con-DC-SCS to induce a possible facilitatory or pronociceptive mode of action of descending serotonergic projections on the spinal nociceptive network.

In conclusion. Conventional stimulation of the dorsal columns result in increased 5-HT release in the spinal DH of the SCS-responding chronic neuropathic rat. Con-DC-SCS results in antinociception and reverses the pronociceptive effect of the descending serotonergic projections as seen in chronic neuropathic rodents. This involves the 5-HT2, 5-HT3, 5-HT4 receptors (see Figure 2(c)).

Summary and discussion

Summary

In the healthy adult rodent, descending serotonergic modulation of nociceptive transmission in the dorsal horn is inhibitory, acting through the 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3 and 5-HT4 receptor.

In chronic pain, the balance tips towards facilitation (and pronociception) which is mediated via injury-induced changes of the descending serotonergic system. Besides a reduced 5-HT content, peripheral nerve injury resulted in upregulated excitatory receptors (5-HT2a, 5-HT2b, 5-HT3) and changes in functionality of spinal 5-HT2a/c, 5-HT2b, 5-HT3, 5-HT4 and 5-HT7 receptors. Con-DC-SCS restores the balance from pro- to antinociception and this is mediated by 5-HT2, 5-HT3 and 5-HT4 receptors. Similar to the normal healthy situation, the GABAergic ININ pathway is important for
mediating the inhibitory and antinociceptive effect of the 5-HT3 receptor in con-DC-SCS induced analgesia.

Cortical control of descending 5-HT modulation

Although the topic of this systematic review is to collect all data and information on the serotonergic modulation nociception in the spinal cord, (sub)cortical modulation and the role of 5-HT on nociception must not be overlooked. Noxious stimuli activate a variety of brain regions such as the primary and secondary sensory cortices, the anterior cingulate cortex (ACC), prefrontal cortex (PFC), insula, amygdala and thalamus. The periaqueductal grey (PAG), located in the midbrain, receives input from these areas and projects to the RVM. The PAG is an important regulator of serotonergic descending modulation through its connections with the RVM.

Besides descending modulation of nociception, 5-HT is involved in ascending modulation of nociception as well. Ascending serotonergic fibers originate from the raphe nuclei and project to a variety of brain areas. The application of 5-HT or 5-HT receptor agonists and/or antagonists modulates nociception by acting on these brain areas that express serotonin receptors.

Similarly as to the spinal cord, supraspinal areas or their connectivity are subject to changes upon chronic pain and are activated upon DC-SCS with both conventional and burst paradigms.

Clearly, effects of serotonergic drugs and/or neuromodulatory treatments on supraspinal brain regions that are involved in nociception and pain that express serotonin receptors must not be overlooked in the development of new treatments.

Pharmacological interventions for chronic pain: Role for serotonergic drugs?

Pharmacological interventions in the treatment of neuropathic pain are often complicated as they are accompanied by substantial side-effects which cause them to be discontinued. Currently, pharmacological treatment paradigms include the use of tricyclic antidepressants such as amitriptyline and serotonin-noradrenalin reuptake inhibitors (SNRIs) such as duloxetine.

Since 5-HT receptors are subject to change after injury, specific targeting of these receptors is recommended for better treatment of neuropathic pain. Since the 5-HT2b receptor does not seem to be involved in nociceptive modulation in the healthy rodent but does exert a facilitatory role in neuropathic rodents, this receptor may be an important candidate for pharmacological treatment and the development of a selective antagonist. As the 5-HT5a and 5-HT7 receptors seem to show increased inhibitory function upon injury, the activation of these receptors with the use of very specific agonists may flip the overall balance from pro- to antinociception.

5-HT also plays a role in nerve injury-induced long term potentiation of synapses within the spinal cord that contribute to chronic pain, in one way by transforming silent glutamatergic synapses in the spinal dorsal horn into functional synapses. Future studies on elucidating the exact involvement of 5-HT in this transformation process and LTP is needed to further understand the mechanism of action underlying use of serotonergic drug or neuromodulatory treatments in chronic pain.

Combination of serotonergic drugs and SCS: Rescuing non-responders?

Unfortunately, of the patients that receive con-DC-SCS, about 30% of patients to not experience clinically relevant pain relief and are classified as nonresponders. The combination of serotonergic drug treatment and con-DC-SCS might also lead to a better treatment for neuropathic pain patients. Preclinical work from Song et al. showed that increased 5-HT release in the spinal cord was only observed in rats responding to con-DC-SCS and that the combination with subclinical doses of intracereally applied serotonergic drugs could enhance the SCS-induced analgesic effect and turn nonresponders to con-DC-SCS into responders. Other examples of turning nonresponders into responders with the use of sub-effective drug dose application are ketamine or the GABA antagonist baclofen. Because 5-HT is clearly involved in mediating con-DC-SCS-induced analgesia, combinational therapy of serotonergic drugs and SCS may potentially be of use in rescuing patients that do not respond to SCS treatment alone. Antidepressants have been used as adjuvant therapy in both preclinical and clinical studies, resulting in an enhanced effectivity of con-DC-SCS and improvements on McGill pain questionnaire and willingness to repeat SCS surgery, respectively. Because of the close entanglement with the GABAergic system, modulation of 5-HT3 receptors might be of specific interest.

New SCS-paradigms: A more prominent role of descending serotonergic projections and spinal nociception?

As briefly mentioned in the Descending serotonergic projections and spinal nociception: Spinal cord stimulation in chronic neuropathic rodents section, there are recently developed and new SCS stimulation paradigms which are now tested in neuropathic pain patients such as burst and high frequency SCS (reviewed in Heijmans and Joosten, 2020). Burst-SCS is a paradigm that delivers periodic bursts of multiple pulses to the dorsal
column. Based on EEG and imaging studies,^{119,129,130} and the behavioral observation that burst-SCS has a delayed onset of efficacy and a prolonged duration of efficacy after discontinuation of stimulation, when compared to con-SCS,^{131} it is suggested that burst-SCS activates both the medial and lateral ascending spinothalamic tract whereas con-DC-SCS only seems to activate the lateral.^{128} The medial pathway is known to be involved in processing emotional, affective components of pain and engages the RVM and PAG in a descending feedback loop to the spinal DH.^{64} Burst-SCS activates the anterior cingulate cortex and amygdala (among other brain areas) to a higher extent with than con-DC-SCS and these areas provide output to the RVM and the PAG.^{119} As the RVM and PAG are important brain areas in serotonergic descending modulation,^{109} it can be speculated that serotonin plays a role in the analgesic mechanisms of burst-SCS, likely even more than with con-DC-SCS and it will be meaningful to investigate this. Gaining a better understanding of the involvement of the descending serotonergic system in the underlying mechanisms of new SCS paradigms like burst-SCS is therefore of utmost importance.

**Future directions**

**Resolving knowledge gaps.** Besides the relatively extensive amount of research on the involvement of serotonin in nociceptive transmission in the healthy rodent and in the neuropathic pain rodent, there remain some important gaps in the current knowledge on the topic that should be addressed in future studies. Firstly, further clarification on the expression of the 5-HT receptors (see Table 1) on the different cell types within the dorsal horn may help the interpretation of behavioral or electrophysiological results and eliminate speculation both in the healthy rodent and after the induction of neuropathic pain. Secondly, present literature on changes in 5-HT expression in the DH after injury is rather conflicting, which may be due to different pain models used. Studies aimed at, or including, the evaluation of changes in 5-HT content or descending serotonergic terminals in the DH after injury may provide more clarity. Thirdly, identifying changes in 5-HT receptor expression and function upon injury will help pinpoint pharmacological targets for a more successful use of serotonergic drugs in the treatment of chronic neuropathic pain.

**Limitations of included studies.** There are some limitations to the studies included in this review that must be addressed. First of all, the use of different pain models and the differences in experimental design and lack of standardization between studies complicates the interpretation of results. Many aspects may affect the net effect of the bidirectional serotonergic modulation such as dose of serotonergic agent, drug administration route (intrathecal, systemic, intraplantar or intraventricular), as well as the time point of testing after induction of the neuropathy (e.g. 7 DPI vs 14 DPI). These should all be considered when comparing the results of different preclinical studies.

Another important point complicating the interpretation of the reviewed literature is that many of the serotonergic drugs used in the studies are not exclusively binding to one receptor subtype. The 5-HT1a agonist 8-OH-DPAT also has affinity for the 5-HT7 receptor.^{132} Similarly, many studies designate ketanserin as a 5-HT2a antagonist whereas it also has affinity for other 5-HT2 receptors. Furthermore, studies using the nonspecific serotonergic drugs methysergide or methiothepin that claim a receptor specific effect must be interpreted with extreme caution. At present, more selective serotonergic drugs are being developed, hopefully this will resolve this problem and provide very detailed and exclusive outcomes.

Lastly, the utilization of behavioral tests should be critically evaluated. Many of the behavioral studies included in this review evaluate evoked pain using reflex based tests, such as the tail flick test, hot plate test and paw withdrawal tests. To assess spontaneous pain or evaluate the effects of interventions that involve supraspinal mechanisms known to be involved in pain, future studies should extend the behavioral test repertoire to include not only evoked pain tests but also tests related to cognitive and emotional aspects of pain such as Conditioned Placed Preference^{133} or the Mechanical Conflict Avoidance System.^{134} This then could also employ diffuse noxious inhibitory controls as a way of evaluating descending inhibition and serotonergic involvement herein.^{135–139} Serotonin is also involved in the regulation of locomotion.^{140} The use of serotonergic drugs at concentrations that induce motor effects may lead to incorrect interpretation of test results. Future studies utilizing serotonergic drugs should include some form of locomotion testing or incorporate a pilot study to select a correct dosage that does not induce locomotion effects.

**Risk of bias.** The RoB analysis was performed on all studies included in the review (Appendix 5). Results showed overall good reporting of baseline characteristics and studies were generally free of selective reporting bias. Randomization (sequence generation, allocation concealment, random housing and random outcome collection) and blinding during the study as well as analysis are not well reported on. Incomplete outcome data was a high risk of bias in quite a lot of articles and should be reported more meticulously. Other potential biases such
as conflict of interest and general study design were generally not well reported.

Conclusion
In the healthy rodent, descending serotonergic modulation of nociceptive transmission in the dorsal horn is inhibitory, acting via the 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3 and 5-HT4 receptor. In chronic neuropathic pain, the balance tips towards facilitation which is mediated by the 5-HT2a, 5-HT2b and 5-HT3 receptor. Con-DC-SCS restores this balance again to an inhibitory mode, which is mediated by 5-HT2, 5-HT3 and 5-HT4 receptors. Future studies with use of new SCS paradigms might benefit from additional use of very selective and sub-effective dose of drugs modulating the serotonergic descending pathway.

Author Contributions
LH and EAJ conceptualized and designed review setup. LH conducted literature search, article inclusion and review of articles + data extraction. LH and MRM performed risk of bias analysis. LH wrote the manuscript. EAJ and MRM provided critical evaluation of the manuscript. All authors agree on the final version of the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Lonne Heijmans https://orcid.org/0000-0002-0927-0408

Supplemental Material
Supplemental material for this article is available online.

References
1. Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care 2014; 8: 143–151.
2. Loeher JD, Treede R-D. The Kyoto protocol of IASP basic pain terminology. Pain 2008; 137: 473–477.
3. Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol 2011; 22: 390–404.
4. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355–474.
5. Benarroch EE. Dorsal horn circuitry: complexity and implications for mechanisms of neuropathic pain. Neurology 2016; 86: 1060–1069.
6. Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 2010; 11: 823–836.
7. Braz JM, Nassar MA, Wood JN, Basbaum AI. Parallel “pain” pathways arise from subpopulations of primary afferent nociceptor. Neuron 2005; 47: 787–793.
8. Polgár E, Puskár Z, Watt C, Matesz C, Todd AJ. Selective innervation of lamina I projection neurones that possess the neurokinin 1 receptor by serotonin-containing axons in the rat spinal cord. Neuroscience 2002; 109: 799–809.
9. Jones SL, Light AR. Termination patterns of serotonergic medullary raphespinal fibers in the rat lumbar spinal cord: an anterograde immunohistochemical study. J Comp Neurol 1990; 297: 267–282.
10. Laporte AM, Fattaccini CM, Lombard MC, Chauveau J, Hamon M. Effects of dorsal rhizotomy and selective lesion of serotonergic and noradrenergic systems on 5-HT1A, 5-HT1B, and 5-HT3 receptors in the rat spinal cord. J Neurotransm Gen Sect 1995; 100: 207–223.
11. Doly S, Fischer J, Brisorgueil MJ, Vergè D, Conrath M. 5-HT5A receptor localization in the rat spinal cord suggests a role in nociception and control of pelvic floor musculature. J Comp Neurol 2004; 476: 316–329.
12. Conte D, Legg ED, McCourt AC, Silajdzic E, Nagy GG, Maxwell DJ. Transmitter content, origins and connections of axons in the spinal cord that possess the serotonin (5-hydroxytryptamine) 3 receptor. Neuroscience 2005; 134: 165–173.
13. Liu FY, Xing GG, Qu XX, Xu JS, Han JS, Wan Y. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats. J Pharmacol Exp Ther 2007; 321: 1046–1053.
14. Maxwell DJ, Kerr R, Rashid S, Anderson E. Characterisation of axon terminals in the rat dorsal horn that are immunoreactive for serotonin 5-HT3A receptor subunits. Exp Brain Res 2003; 149: 114–124.
15. Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burguero J, Zamanillo D, Hamon M, Maldonado R, Vela JM. Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. Pain 2010; 149: 483–494.
16. Brenchat A, Zamanillo D, Hamon M, Romero L, Vela JM. Role of peripheral versus spinal 5-HT(7) receptors in the modulation of pain undersensitizing conditions. Eur J Pain 2012; 16: 72–81.
17. Doly S, Madeira A, Fischer J, Brisorgueil MJ, Daval G, Bernard R, Vergè D, Conrath M. The 5-HT2A receptor is widely distributed in the rat spinal cord and mainly localized at the plasma membrane of postsynaptic neurons. J Comp Neurol 2004; 472: 496–511.
18. Kawamata T, Omote K, Toriyabe M, Yamamoto H, Namiki A. The activation of 5-HT(3) receptors evokes GABA release in the spinal cord. Brain Res 2003; 978: 250–255.
19. Doly S, Fischer J, Brisorgueil MJ, Vergè D, Conrath M. Pre- and postsynaptic localization of the 5-HT7 receptor
in rat dorsal spinal cord: immunocytochemical evidence. *J Comp Neurol* 2005; 490: 256–269.

20. Rahman W, Bannister K, Bee LA, Dickinson AH. A pronociceptive role for the 5-HT2 receptor on spinal nociceptive transmission: an in vivo electrophysiological study in the rat. *Brain Res* 2011; 1382: 29–36.

21. Kidd EJ, Laporte AM, Langlois X, Fattaccini CM, Doyen C, Lombard MC, Gozlan H, Hamon M. 5-HT3 receptors in the rat Central nervous system are mainly located on nerve fibres and terminals. *Brain Res* 1993; 612: 289–298.

22. Daval G, Vergé D, Basbaum AI, Bourgoin S, Hamon M. Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. *Neurosci Lett* 1987; 83: 71–76.

23. Van Steenwinckel J, Noghero A, Thibault K, Brisorgueil MJ, Fischer J, Conrath M. The 5-HT2A receptor is mainly expressed in nociceptive sensory neurons in rat lumbar dorsal root ganglia. *Neuroscience* 2009; 161: 838–846.

24. Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. *J Neurosci* 2002; 22: 1010–1019.

25. Melzack R, Wall PD. Pain mechanisms: a new theory. *Science* 1965; 150: 971–979.

26. Zhuo M. Descending facilitation: from basic science to clinical perspectives. *Adv Exp Med Biol* 1993; 318: 43–03.

27. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. *Mol Pain* 2008; 152: 487–494.

28. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. *Mol Pain* 2008; 152: 487–494.

29. Kuraishi Y, Hirota N, Satoh M, Takagi H. Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. *Neurosci Lett* 1987; 83: 71–76.

30. Advokat C. Intrathecal coadministration of serotonin and morphine differentially modulates the tail-flick reflex of intact and spinal rats. *Brain Res* 2002; 910: 101–109.

31. Lu Y, Perl ER. Selective action of noradrenaline on nociceptive neurons of the spinal superficial dorsal horn in the rat. *J Physiol* 2007; 582: 127–136.

32. Fasmer OB, Berge OG, Hole K. Changes in nociception after lesions of descending serotonergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests. *Neuropharmacology* 1985; 24: 729–734.

33. Qu CL, Huo FQ, Huang FS, Li YQ, Tang JS, Jia H. The role of 5-HT receptor subtypes in the ventrolateral orbital cortex of 5-HT-induced antinociception in the rat. *Neuroscience* 2008; 152: 487–494.

34. Xiao DQ, Tang JS, Yuan B, Jia H. Inhibitory effects of 5-hydroxytryptamine microinjection into thalamic nucleus submedius on rat tail flick reflex are mediated by 5-HT2 receptors. *Neurosci Lett* 1999; 260: 85–88.

35. Xiao DQ, Zhu JX, Tang JS, Jia H. 5-hydroxytryptamine 1A (5-HT1A) but not 5-HT3 receptor is involved in mediating the nucleus submedius 5-HT-evoked antinociception in the rat. *Brain Res* 2005; 1046: 38–44.

36. Berge OG. Effects of 5-HT receptor agonists and antagonists on a reflex response to radiant heat in normal and spinaly transected rats. *Pain* 1982; 13: 253–266.

37. Meller SL, Lewis SJ, Ness TJ, Brody MJ, Gebhart GFF. Vagal afferent-mediated inhibition of a nociceptive reflex by intravenous serotonin in the rat. *J Pharmacol Exp Ther* 1990; 294: 90–100.

38. Colpaert FC, Tararye JP, Koek W, Pauwels PJ, Bardin L, Xu XJ, Wiesenfeld-Hallin Z, Cosi C, Carilla-Durand E, Assié MB, Vacher B. Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, Central analgesia. *Neuropharmacology* 2002; 43: 945–958.

39. Lin Q, Peng YB, Willis WD. Antinociception and inhibition from the periaqueductal gray are mediated in part by spinal 5-hydroxytryptamine1A receptors. *J Pharmacol Exp Ther* 1996; 276: 958–967.

40. Nadezon R, Goodchild CS. Antinociceptive role of 5-HT1A receptors in rat spinal cord. *Br J Anaesth* 2002; 88: 679–684.

41. Gjerstad J, Tjølsen A, Hole K. The effect of 5-HT1A receptor stimulation on nociceptive dorsal horn neurones in rats. *Eur J Pharmacol* 1996; 318: 315–321.

42. Peng YB, Lin Q, Willis WD. The role of 5-HT3 receptors in periaqueductual gray-induced inhibition of nociceptive dorsal horn neurones in rats. *J Pharmacol Exp Ther* 1996; 276: 116–124.

43. You HJ, Colpaert FC, Arendt-Nielsen L. The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. *Exp Neurol* 2005; 191: 174–183.

44. Aira Z, Buesa I, Salgueiro M, Bilbao J, Aguilera L, Zimmermann M, Azkue JJ. Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury. *Neuroscience* 2010; 168: 831–841.

45. Gjerstad J, Tjølsen A, Hole K. A dual effect of 5-HT1B receptor stimulation on nociceptive dorsal horn neurones in rats. *Eur J Pharmacol* 1997; 335: 127–132.

46. Ali Z, Wu G, Kozlov A, Barasi S. The actions of 5-HT1 agonists and antagonists on nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. *Brain Res* 1994; 661: 83–90.

47. Monroe PJ, Smith DJ. Demonstration of an autoreceptor modulating the release of [3H]-5-Hydroxytryptamine from a synaptosomal-rich spinal cord tissue preparation. *J Neurochem* 1985; 45: 1886–1894.

48. Nitanda A, Yasunami N, Tokumo K, Fujii H, Hirai T, Nishio H. Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain. *Neurochem Int* 2005; 47: 394–400.

49. Allhainder A, Lei S, Wilcox G. Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. *J Neurosci* 1991; 11: 1881–1888.
in rats suffering from neuropathic pain. Neuropharmacology 2012; 63: 1093–1106.
64. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267–284.
65. Leong ML, Gu M, Speltz-Paiz R, Stahura EJ, Mottey N, Steer CJ, Wessendorf M. Neuronal loss in the rostral ventromedial medulla in a rat model of neuropathic pain. J Neurosci 2011; 31: 17028–17039.
66. Song Z, Uldenius C, Meyerson BA, Linderoth B. Pain relief by spinal cord stimulation involves serotonergic mechanisms: an experimental study in a rat model of mononeuropathy. Pain 2009; 147: 241–248.
67. Vogel C, Mössner R, Gerlach M, Heinemann T, Murphy DL, Riederer P, Lesch K-P, Sommer C. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci 2003; 23: 708–715.
68. Gautier A, El Ouaraki H, Bazin N, Salam S, Vodjdani G, Bourgon S, Pezet S, Bernard JF, Hamon M. Lentiviral vector-driven inhibition of 5-HT receptors in B3 bulbospinal serotoninergic projections – consequences on nociception, inflammatory and neuropathic pain in rats. Exp Neurol 2017; 288: 11–24.
69. Morgado C, Silva L, Pereira-Terra P, Tavares I. Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1. Neurobiol Dis 2011; 43: 275–284.
70. Ramer LM, Borisoff JF, Ramer MS. Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. J Neurosci 2004; 24: 10796–10805.
71. Satoh O, Omote K. Roles of monoaminergic, glycnergic and GABAergic inhibitory systems in the spinal cord in rats with peripheral mononeuropathy. Brain Res 1996; 728: 27–36.
72. Hoshino H, Obata H, Saito S. Antihyperalgesic effect of duloxetine and amitriptyline in rats after peripheral nerve injury: influence of descending noradrenergic plasticity. Neurosci Lett 2015; 602: 62–67.
73. Peters CM, Hayashida KI, Ewan EE, Nakajima K, Obata H, Xu Q, Yaksh TL, Eisenach JC. Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat. Brain Res 2010; 1352: 83–93.
74. Avila-Rojas SH, Velázquez-Lagunas I, Salinas-Abarca AB, Barragán-Iglesias P, Pineda-Farias JB, Granados-Soto V. Role of spinal 5-HT5 receptors in the regulation of neuropathic hypersensitivity in the rat. Eur J Pharmacol 2011; 664: 377–385.
75. Wei H, Pertovaara A. 5-HT(1A) receptors in endogenous regulation of neuropathic hypersensitivity in the rat. Eur J Pharmacol 2006; 553: 157–165.
76. Obata H, Saito S, Sakurazawa S, Sasaki M, Usui T, Goto F. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury. Pain 2004; 108: 163–169.
77. Obata H, Saito S, Sasaki M, Goto F. Possible involvement of a muscarinic receptor in the anti- allodynic action of a 5-HT2 receptor agonist in rats with nerve ligation injury. Brain Res 2002; 932: 124–128.
78. Sasaki M, Obata H, Saito S, Goto F. Antinociception with intrathecal alpha-methyl-5-hydroxytryptamine, a 5-hydroxytryptamine 2A/2C receptor agonist, in two rat models of sustained pain. *Anesth Analg* 2003; 96: 1072–1078.

79. Honda M, Uchida K, Tanabe M, Ono H. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. *Neuropharmacology* 2006; 51: 866–872.

80. Kim YS, Chu Y, Han L, Li M, Li Z, LaVinka PC, Sun S, Tang Z, Park K, Caterina MJ, Ren K, Dubner R, Wei F, Dong X. Central terminal sensitization of TRPV1 by descending serotonergic facilitation modulates chronic pain. *Neuron* 2014; 81: 873–887.

81. Okazaki R, Namba H, Yoshida H, Okai H, Miura T, Kawamura M. The antiallodynic effect of neurotropin is mediated via activation of descending pain inhibitory systems in rats with spinal nerve ligation. *Anesth Analg* 2008; 107: 1064–1069.

82. Pertovaara A, Keski-Vakkuri U, Kalmari J, Wei H, Panula P. Response properties of neurons in the rostroventromedial medulla of neuropathic rats: attempted modulation of responses by [1DMe]NPYF, a neuropeptide FF analogue. *Neuroscience* 2001; 105: 457–468.

83. Cragg JJ, Scott AL, Ramer MS. Depletion of spinal 5-HT accelerates mechanosensory recovery in the deafferented rat spinal cord. *Exp Neurol* 2010; 222: 277–284.

84. Wei F, Dubner R, Zou S, Ren K, Bai G, Wei D, Guo W. Molecular depletion of descending serotonin unmasks its novel facilitatory role in the development of persistent pain. *J Neurosci* 2010; 30: 8624–8636.

85. Rahman W, Suzuki R, Webber M, Hunt SP, Dickenson AH. Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation. *Pain* 2006; 123: 264–274.

86. Aira Z, Buesa I, Gallego M, García del Caño G, Mendiable N, Mingo J, Rada D, Bilbao J, Zimmermann M, Azkue JJ. Time-dependent cross talk between spinal serotonin 5-HT2A receptor and mGluR1 subserves spinal hyperexcitability and neuropathic pain after nerve injury. *J Neurosci* 2012; 32: 13568–13581.

87. Lopez-Alvarez VM, Puigdomenech M, Navarro X, Cobianchi S. Monoaminergic descending pathways contribute to modulation of neuropathic pain by increasing-intensity treadmill exercise after peripheral nerve injury. *Exp Neurol* 2018; 299: 42–55.

88. Aira Z, Buesa I, G. del Caño G, Salgueiro M, Mendiable N, Mingo J, Aguilera L, Bilbao J, Azkue JJ. Selective impairment of spinal mu-oupioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors. *Pain* 2012; 153: 1418–1425.

89. Chang EY, Chen X, Sandhu A, Li CY, Luo ZD. Spinal 5-HT3 receptors facilitate behavioural hypersensitivity induced by elevated calcium channel alpha-2-Delta-1 protein. *Eur J Pain* 2013; 17: 505–513.

90. Dogrul A, Ossipov MH, Porreca F. Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. *Brain Res* 2009; 1280: 52–59.

91. Wang R, King T, De Felice M, Guo W, Ossipov MH, Porreca F. Descending facilitation maintains long-term spontaneous neuropathic pain. *J Pain* 2013; 14: 845–853.

92. Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. *Brain Res* 2004; 1019: 68–76.

93. Amaya-Castellanos E, Pineda-Farias JB, Castañeda-Corral G, Vidal-Cantú GC, Murbartíán J, Rocha-González HI, Granados-Soto V. Blockade of 5-HT7 receptors reduces tactile allodynia in the rat. *Pharmacol Biochem Behav* 2011; 99: 591–597.

94. Geurts JW, Joosten EA, van Kleef M. Current status and future perspectives of spinal cord stimulation in treatment of chronic pain. *Pain* 2017; 158: 771–774.

95. Deer T, Slavin KV, Amirdelfan K, North RB, Burton AW, Yearwood TL, Tavel E, Staats P, Falowski S, Pope J, Justiz R, Fabi AY, Taghva A, Piccius R, Houden T, Wilson D. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. *Neuromodulation* 2018; 21: 56–66.

96. Kemler MA, Barendse GAM, van Kleef M, de Vet HCW, Rijks CPRM, Furnée CA, van den Wildenberg FAJM. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J Med* 2000; 343: 618–624.

97. North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. *Neurosurgery* 2005; 56: 98–107.

98. Slanger R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, van Dongen RT, Kessels AG, van Kleef M. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. *Dia Care* 2014; 37: 3016–3024.

99. Shealy CN, Taslitz N, Mortimer JT, Becker DP. Electrical inhibition of pain: experimental evaluation. *Anesth Analg* 1967; 46: 299–305.

100. Miller JP, Eldabe S, Buchser E, Johaneck LM, Guan Y, Linderoth B. Parameters of spinal cord stimulation and their role in electrical charge delivery: a review. *Neuromodulation* 2016; 19: 373–384.

101. Smits H, van Kleef M, Joosten EA. Spinal cord stimulation of dorsal columns in a rat model of neuropathic pain: evidence for a segmental spinal mechanism of pain relief. *Pain* 2012; 153: 177–183.

102. Slangen R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, van Dongen RT, Kessels AG, van Kleef M. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. *Dia Care* 2014; 37: 3016–3024.
Spinal cord stimulation modulates supraspinal centers of the descending antinociceptive system in rats with unilateral spinal nerve injury. *Mol Pain* 2015; 11: 36.

105. Song Z, Meyerson BA, Linderoth B. Spinal 5-HT receptors that contribute to the pain-relieving effects of spinal cord stimulation in a rat model of neuropathy. *Pain* 2011; 152: 1666–1673.

106. Saadé NE, Burchini J, Tchachaghian S, Chamaa F, Jabbur SJ, Song Z, Meyerson BA, Linderoth B. The role of the dorsolateral funiculi in the pain relieving effect of spinal cord stimulation: a study in a rat model of neuropathic pain. *Exp Brain Res* 2015; 233: 1041–1052.

107. Veinante P, Yalcin I, Barrot M. The amygdala between sensation and affect: a role in pain. *J Mol Psychiatry* 2013; 1: 9.

108. Ong W-Y, Stohler CS, Herr DR. Role of the prefrontal cortex in pain processing. *Mol Neurobiol* 2019; 56: 1137–1166.

109. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. *J Clin Invest* 2010; 120: 3779–3787.

110. Calejesan AA, Kim SJ, Zhuo M. Descending facilitatory modulation of a behavioral nociceptive response by stimulation in the adult rat anterior cingulate cortex. *Eur J Pain* 2000; 4: 83–96.

111. Wei F, Gu M, Chu YX. New tricks for an old slug: descending serotonergic system in pain. *Sheng Li Xue Bao* 2012; 64: 520–530.

112. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. *J Comp Neurol* 1978; 179: 641–667.

113. Qu CL, Tang JS. Roles of ventrolateral orbital cortex in pain modulation and acupuncture analgesia. *Sheng Li Ke Xue Jin Zhan* 2008; 39: 297–301.

114. Prado WA, Faganello FA. The anterior pretectal nucleus participates as a relay station in the glutamate-, but not morphine-induced antinociception from the dorsal raphe nucleus in rats. *Pain* 2000; 88: 169–176.

115. Souvoravong S, Nakashima MN, Wada M, Nakashima K. Decrease in serotonin concentration in raphe magnus nucleus and attenuation of morphine analgesia in two mice models of neuropathic pain. *Eur J Pharmacol* 2004; 484: 217–223.

116. Tan LL, Pelzer P, Heinl C, Tang W, Gangadharan V, Flor H, Sprengel R, Kuner T, Kuner R. A pathway from midcingulate cortex to posterior insula gates nociceptive hypersensitivity. *Nat Neurosci* 2017; 20: 1591–1601.

117. Goettl VM, Huang Y, Hackshaw KV, Stephens RL Jr. Reduced basal release of serotonin from the ventrobasal thalamus of the rat in a model of neuropathic pain. *Pain* 2002; 99: 359–366.

118. Huang J, Gadotti VM, Chen L, Souza IA, Huang S, Wang D, Ramakrishnan C, Deisseroth K, Zhang Z, Zamponi GW. A neuronal circuit for activating descending modulation of neuropathic pain. *Nat Neurosci* 2019; 22: 1659–1668.

119. Meuwissen KPV, van der Toorn A, Gu JW, Zhang TC, Dijkhuizen RM, Joosten EAJ. Active recharge burst and tonic spinal cord stimulation engage different supraspinal mechanisms: a functional magnetic resonance imaging study in peripherally injured chronic neuropathic rats. *Pain Prac* 2020; 20: 510–521.

120. Bonezi C, Fornasari D, Cricelli C, Magni A, Ventriglia G. Pharmacological management of adults with chronic non-cancer pain in general practice. *Pain Ther* 2020; 9: 17–28.

121. Schug SA, Goddard C. Recent advances in the pharmacological management of acute and chronic pain. *Ann Palliat Med* 2014; 3: 263–275.

122. Sandkühler J, Gruber-Schoffnegger D. Hyperalgesia by synaptic long-term potentiation (LTP): an update. *Curr Opin Pharmacol* 2012; 12: 18–27.

123. Zhuo M. Silent glutamatergic synapses and long-term facilitation in spinal dorsal horn neurons. *Prog Brain Res* 2000; 129: 101–113.

124. Truin M, Janssen S, Kleef M, Joosten E. Successful pain relief in non-responders to spinal cord stimulation: the combined use of ketamine and spinal cord stimulation. *Eur J Pain* 2011; 15: 1049.e1041–1049.

125. Ultenius C, Song Z, Lin P, Meyerson B, Linderoth B. Spinal GABAergic mechanisms in the effects of spinal cord stimulation in a rodent model of neuropathic pain: is GABA synthesis involved? *Neuromodulation* 2013; 16: 114–120.

126. Song Z, Meyerson BA, Linderoth B. The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy. *Anesth Analg* 2011; 113: 1260–1265.

127. Prabhala T, Sabourin S, DiMarzio M, Gillogly M, Prusik J, Pilitsis JG. Duloxetine improves spinal cord stimulation outcomes for chronic pain. *Neuromodulation* 2019; 22: 215–218.

128. Heijmans L, Joosten EA. Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain. *Postgrad Med* 2020; 132: 17–21.

129. Thaweerattanasin P, Birch D, Jiang MC, Tresch MC, Bennett DJ, Heckman CJ, Tyszling VM. Bursting interneurons in the deep dorsal horn develop increased excitability and sensitivity to serotonin after chronic spinal injury. *J Neurophysiol* 2020; 123: 1657–1670.

130. Yearwood T, De Ridder D, Yoo HB, Falowski S, Venkatesan L, Ting To W, Vanneste S. Comparison of neural activity in chronic pain patients during tonic and burst spinal cord stimulation using fluorodeoxyglucose positron emission tomography. *Neuromodulation* 2020; 23: 56–63.

131. Meuwissen KPV, Gu JW, Zhang TC, Joosten EAJ. Burst spinal cord stimulation in peripherally injured chronic neuropathic rats: a delayed effect. *Pain Prac* 2018; 18: 988–996.

132. Lov enberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW. A novel adenyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. *Neuron* 1993; 11: 449–458.

133. Davoodi L, Quiton RL, Lucas JM, Ji Y, Keller A, Masri R. Conditioned place preference reveals tonic pain in an animal model of Central pain. *J Pain* 2011; 12: 868–874.
134. Harte SE, Meyers JB, Donahue RR, Taylor BK, Morrow TJ. Mechanical conflict system: a novel operant method for the assessment of nociceptive behavior. PLoS One 2016; 11: e0150164.

135. Bannister K, Lockwood S, Goncalves L, Patel R, Dickenson AH. An investigation into the inhibitory function of serotonin in diffuse noxious inhibitory controls in the neuropathic rat. Eur J Pain 2017; 21: 750–760.

136. Bannister K, Patel R, Goncalves L, Townson L, Dickenson AH. Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations. Pain 2015; 156: 1803–1811.

137. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotoninergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res 1982; 236: 329–337.

138. Dickenson AH, Rivot JP, Chaouch A, Besson JM, Le Bars D. Diffuse noxious inhibitory controls (DNIC) in the rat with or without pCPA pretreatment. Brain Res 1981; 216: 313–321.

139. Zhuo M, Gebhart GF. Inhibition of a cutaneous nociceptive reflex by a noxious visceral stimulus is mediated by spinal cholinergic and descending serotoninergic systems in the rat. Brain Res 1992; 585: 7–18.

140. Jordan LM, Liu J, Hedlund PB, Akay T, Pearson KG. Descending command systems for the initiation of locomotion in mammals. Brain Res Rev 2008; 57: 183–191.